Adalimumab Kit
Product Images NDC 83257-021

30 FDA label images from Biocon Biologics Inc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 30 technical images submitted to the FDA as part of the official labeling for Adalimumab (NDC 83257-021). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Biocon Biologics Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 3: Kaplan-meier Curves Summarizing Time To Treatment Failure On Or After Week 6 (study Uv I) Or Week 2 (study Uv Ii) (Image 27)

Figure 3: Kaplan-meier Curves Summarizing Time To Treatment Failure On Or After Week 6 (study Uv I) Or Week 2 (study Uv Ii) (Image 27)
Two Kaplan-Meier plots showing treatment failure rates over 20 months from two studies, Study UV I and Study UV II, comparing placebo and Adalimumab treatments. The vertical axis is treatment failure rate (%) and the horizontal axis is time in months. Both studies indicate lower failure rates with Adalimumab than placebo throughout the treatment period.*
FDA Label Image

Image-30 (Image 30)

Image-30 (Image 30)
An instructional diagram showing recommended injection sites for Adalimumab on the human body. The illustration highlights the abdomen area, indicating to stay 2 inches away from the belly button, and both thighs as suitable injection locations.*
FDA Label Image

Image-31 (Image 31)

Image-31 (Image 31)
An injection diary table with two columns labeled 'Date' and 'Injection Site Used.' The table includes multiple rows for recording injection dates and corresponding injection sites. No specific data or entries are visible within the table.*
FDA Label Image

Image-32 (Image 32)

Image-32 (Image 32)
An instructional diagram illustrating the components and features of an Adalimumab-fkjp prefilled syringe from Biocon Biologics Inc. The labeled syringe parts include the plunger, fill marker, medicine, needle cap (with a caution not to uncape until injection), strength and expiration date, and an internal needle safety feature that activates after use. The diagram also compares two syringe volume options, 0.4 mL and 0.8 mL, emphasizing matching syringe volume with the prescription.*
FDA Label Image

Image-33 (Image 33)

Image-33 (Image 33)
An instructional illustration showing a hand holding a syringe or injector device. The image highlights how to grip the device, with the label 'Figure B' indicating a specific step in the instructions, related to the Adalimumab kit by Biocon Biologics Inc.*
FDA Label Image

Image-34 (Image 34)

Image-34 (Image 34)
An instructional diagram showing two views of a syringe with measurements labeled. The left syringe indicates a 0.4 mL volume and the right syringe indicates a 0.8 mL volume, highlighting different dose amounts. The syringes have orange finger grips and transparent barrels with liquid inside.*
FDA Label Image

Image-35 (Image 35)

Image-35 (Image 35)
An instructional illustration labeled Figure E showing a step in medication preparation. It depicts one hand pulling a cap off a syringe held in the other hand, highlighting the proper technique for removing the syringe cap before injection.*
FDA Label Image

Image-36 (Image 36)

Image-36 (Image 36)
Illustration showing a hand holding a syringe with an orange safety shield being activated or removed, demonstrating part of the injection safety procedure for the Adalimumab kit by Biocon Biologics Inc.*
FDA Label Image

Image-37 (Image 37)

Image-37 (Image 37)
An instructional illustration labeled 'Figure G' showing a hand gently squeezing the skin at an injection site, labeled as 'Squeeze Site.' This image appears to be part of a guide related to the use or administration of a drug delivery kit.*
FDA Label Image

Image-38 (Image 38)

Image-38 (Image 38)
An instructional illustration showing a hand holding a syringe at a 45-degree angle to the skin, indicating the correct angle for subcutaneous injection. The diagram is labeled as 'Figure H'.*
FDA Label Image

Image-39 (Image 39)

Image-39 (Image 39)
An instructional illustration showing two hands manipulating a syringe-like device, with arrows indicating upward movements for removing components or preparing the device, labeled as Figure I.*
FDA Label Image

Image-40 (Image 40)

Image-40 (Image 40)
An instructional illustration showing a hand holding a used syringe or similar medical device above a sharps disposal container, with an arrow indicating to place the item into the container. The figure is labeled "Figure J."*
FDA Label Image

Image-41 (Image 41)

Image-41 (Image 41)
Illustration of an Adalimumab-fkjp pen injection showing labeled parts including the orange indicator inside the barrel, medicine, fill marker, viewing window, and orange activator with needle inside. Additional small inner gray cap and protective clear cap are depicted. A caution note advises not to uncap until ready to inject.*
FDA Label Image

Image-43 (Image 43)

Image-43 (Image 43)
Illustration showing a hand holding a pre-filled pen injector labeled partially with 'mumab-fkjp', representing the administration device for the adalimumab-fkjp kit by Biocon Biologics Inc.*
FDA Label Image

Image-44 (Image 44)

Image-44 (Image 44)
Illustration showing a hand holding an Adalimumab-fkjp prefilled pen injector. The pen injector is labeled with 'Adalimumab-fkjp Pen Injection' indicating it is part of the Adalimumab kit by Biocon Biologics Inc.*
FDA Label Image

Image-45 (Image 45)

Image-45 (Image 45)
An instructional illustration labeled 'Figure F' showing hands preparing an Adalimumab injection device, with one hand holding a cap and the other holding the injection pen. An arrow points to the cap, indicating it should be removed.*
FDA Label Image

Image-46 (Image 46)

Image-46 (Image 46)
Illustration showing a hand holding an Adalimumab-fkjp pen injection device, labeled with the product name and dosage form, demonstrating proper grip for administration.*
FDA Label Image

Image-47 (Image 47)

Image-47 (Image 47)
Illustration labeled Figure H showing a syringe or vial with a magnified section highlighting the presence of air bubbles inside the liquid. The image points out 'Air Bubbles' next to the circled area.*
FDA Label Image

Image-48 (Image 48)

Image-48 (Image 48)
An illustration showing a hand holding or gripping a rounded object, likely depicting a step or technique related to the usage of the Adalimumab kit. The figure is labeled 'Figure I'.*
FDA Label Image

Image-49 (Image 49)

Image-49 (Image 49)
An instructional illustration showing a person holding and administering a pen injector device at a 90-degree angle to the skin, demonstrating the proper injection technique for the Adalimumab kit by Biocon Biologics Inc.*
FDA Label Image

Image-50 (Image 50)

Image-50 (Image 50)
Illustration labeled 'Figure K' showing a hand pressing a device onto skin to activate it with a first click, holding down for 10 seconds, observing an orange indicator, following a second click, and a 10-second timer to guide usage. The steps are visually indicated with a sequence bar counting seconds up to 10.*
FDA Label Image

Image-51 (Image 51)

Image-51 (Image 51)
Illustration labeled 'Figure L' showing part of an Adalimumab Pen kit. It highlights the orange needle sleeve and the orange indicator on the pen device, which is partially visible with the label 'Ada Pen'.*
FDA Label Image

Image-52 (Image 52)

Image-52 (Image 52)
Instructional illustration showing a hand holding a syringe or pen device labeled Adalimumab, positioned above a forearm with the other hand pinching the skin, indicating the injection site for the medication.*
FDA Label Image

Image-53 (Image 53)

Image-53 (Image 53)
An instructional illustration showing a hand disposing of a used syringe into a sharps disposal container. The image highlights safe disposal procedures, with an arrow indicating the syringe being dropped into the container's opening.*
FDA Label Image

Image-54 (Image 54)

Image-54 (Image 54)
An illustration labeled 'Figure B' showing an Adalimumab-fkjp Pen Injection with a fill marker and medicine inside the pen. The image notes that it is normal to see one or more air bubbles within the medicine section.*
FDA Label Image

Image-55 (Image 55)

Image-55 (Image 55)
The packaging label for Adalimumab-fkjp Injection, 20 mg/0.4 mL syringe, a kit containing 2 single-dose prefilled syringes. The label shows it is for subcutaneous use only and labeled by Biocon Biologics Inc. The box displays dosage strength, administration instructions, storage requirements, and includes the NDC 83257-020-42.*
FDA Label Image

Image-56 (Image 56)

Image-56 (Image 56)
Packaging label for Adalimumab-fkjp Injection 40 mg/0.8 mL syringe, a kit containing 2 single-dose prefilled syringes. The label shows Biocon Biologics Inc as the manufacturer. The box cautions for subcutaneous use only, provides storage instructions, and includes a barcode and variable data information box for online printing.*
FDA Label Image

Image-57 (Image 57)

Image-57 (Image 57)
Packaging label for Adalimumab-fkjp Pen Injection Kit by Biocon Biologics Inc. The kit contains 2 single-dose prefilled pens, each pen delivering 40 mg/0.8 mL of adalimumab-fkjp for subcutaneous use. The label includes dosage form, strength, usage instructions, storage information, and barcode.*
FDA Label Image

Figure 1. Study Ra-iii Acr 20 Responses Over 52 Weeks (Image 01)

Figure 1. Study Ra-iii Acr 20 Responses Over 52 Weeks (Image 01)
A line graph depicting the percentage of ACR20 responders over time (weeks) up to 48 weeks. It features two data series represented by solid squares and open circles, showing their respective response trends across the study period.*
FDA Label Image

Figure 2. Asas 20 Response By Visit, Study As-i (Image 02)

Figure 2. Asas 20 Response By Visit, Study As-i (Image 02)
A line chart comparing the percentage of ASAS 20 response over 26 weeks between Adalimumab and Placebo groups. The X-axis represents time in weeks, and the Y-axis shows the percentage response. The Adalimumab group shows a higher response rate throughout the period compared to the Placebo group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.